when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVO · news · pharmadog

← back to NOVO

News mentioning NOVO

476 stories

Aug 3, 26Novo’s late-stage IL-6 stumble shakes inflammation spacebiospace

Aug 3, 26Amgen hit with cybersecurity breach, patient data affectedbiospace

Aug 3, 265 companies advancing ATTR assets in the wake of Wainua’s failbiospace

Aug 2, 26STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricingstat

Jul 31, 26STAT+: Trump administration revises rebate pilot for 340B drug discount program, angering hospitalsstat

Jul 31, 26Novo setback casts doubt on a new way to treat heart diseasebiopharma dive

Jul 31, 26Novo Nordisk rocked by late-stage cardiovascular drug failureendpoints

Jul 31, 26Novo's IL-6 inhibitor fails in cardiovascular Phase 3, plunging shares more than 9%biospace

Jul 31, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Jul 31, 26STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and morestat

Jul 31, 26STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease studystat

Jul 31, 26‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreefiercebiotech

Jul 31, 26Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 failfiercebiotech

Jul 30, 26Chutes & Ladders—Legend CEO departs without successor in placefiercebiotech

Jul 29, 26Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapybiospace

Jul 29, 267 companies hiring in New York nowbiospace

Jul 29, 26Novo ordered to face CagriSema fraud claims from shareholders: New Jersey courtbiospace

Jul 29, 26Novo Nordisk fails to dismiss lawsuit over CagriSema readoutfiercebiotech

Jul 29, 26Biotechs bring big launches and pharma rivalries into Q2 earnings periodbiospace

Jul 28, 26FDA offers updated guidance for generics of weight loss blockbustersendpoints

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 28, 26An eye drug biotech banks $118M and stocks its executive suitebiopharma dive

Jul 28, 26Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder winfiercebiotech

Jul 27, 26‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drugfiercebiotech

Jul 27, 26Denmark’s foundation‑fueled biotech boom redraws the Nordic mapbiospace

Jul 24, 26Novo asks court to block Lilly ads; Merck strikes HIV PrEP dealendpoints

Jul 24, 26Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomabiopharma dive

Jul 24, 26Summit has less than a year of cash runway left as PD-1/VEGF verdict nearsbiospace

Jul 24, 26STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pillstat

Jul 23, 26Chutes & Ladders—Biogen R&D vet gets in Formationfiercebiotech

← prevpage 11 of 16next →